Please login to the form below

Not currently logged in
Email:
Password:

Immatics

This page shows the latest Immatics news and features for those working in and with pharma, biotech and healthcare.

Roche pays $1bn-plus for stake in genomics specialist

Roche pays $1bn-plus for stake in genomics specialist

In 2013 Roche licensed a series of early-stage cancer immunotherapy programmes from German company Immatics in a deal valued at more than $1bn, and promised up to $422.5m to

Latest news

More from news
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    was Amgen with the purchase of Immatics' next-generation, T-cell engaging bispecific immunotherapies. ... Immatics. Amgen. Licence /  joint development. Next-generation, T-cell engaging bispecific immuno-therapies .

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    hyperactivity disorder, pain, urology and allergy. 1, 600. immatics / Roche.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Peter Chambre joins cancer vaccine biotech Immatics Peter Chambre joins cancer vaccine biotech Immatics

    Paul Higham, CEO of Immatics, said: “I am delighted to welcome Peter as our new chairman. ... He said: “Immatics' vaccines, based on the company's highly rational approach to cancer vaccine discovery, have already demonstrated very promising results

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics